PREVIOUSLY UNCLASSIFIED MUTATIONS AT POSITIONS ASSOCIATED WITH ANTIRETROVIRAL DRUG RESISTANCE Antiviral Therapy 2004; 9:S156

D67G (2.3%), D67E (0.9%), T69N (7.3%), T69S (3.2%), T69A (1.5%), L74I (3.7%), T215I (2.1%), T215V (1.4%), K219N (3.0%), K219R (2.5%); NNRTIs - K101Q (7.5%), K101P (2.0%), K101H (1.6%), K101N (1.0%), K103S (2.4%); PIs - K20T (3.2%), K20V (0.7%), L33I (2.3%), M36V (2.6%), M46V (0.7%), I54T (1.2%), A71I (3.0%). For 12 additional mutations, the association with treatment was weaker but also significant (P<0.05 but >0.001): NRTIs - T69I (0.6%), K70G (0.6%), K70E (0.3%), K219W (0.3%); NNRTIs - K101R (2.1%), Y181V (0.7%); PIs - L24F (0.7%), M36L (1.5%), G48M (0.2%), F53Y (0.5%), I54S (0.2%), N88T (0.3%). 21% of sequences from persons receiving NRTIs had ≥1 unclassified NRTI mutation. 10% of sequences from persons